Nouran A. Taha

Nouran A. Taha

Auto-generated profile, based on publicly available information

Nouran A. Taha

MARS-Global, London, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2025 in Discover Nano
Verified
Journal Article
Open access
PDF file
MTMuhammad Talaat
Muhammad Talaat
HHHamsa Hassan
Hamsa Hassan
EMEthar Ahmed Mosilhy
Ethar Ahmed Mosilhy
NTNouran A. Taha
Nouran A. Taha
MEMohamed Elsaid
Mohamed Elsaid
MSMahmoud E. Soliman
Mahmoud E. Soliman
Antioxidants showed usefulness in treating or preventing neurodegenerative diseases (NDDs). However, antioxidants have limited bioavailability owing to the

1 January 2024 in Global Pediatric Health
Verified
Journal Article
Open access
MAMohammed Alsabri
Mohammed Alsabri
Abdelmonem SiddiqAbdelmonem Siddiq
Abdelmonem Siddiq
NANicholas Aderinto
Nicholas Aderinto
IIIbukunoluwa V. Ishola
Ibukunoluwa V. Ishola
MSMuhammad Azan Shahid
Muhammad Azan Shahid
LGLuis L Gamboa
Luis L Gamboa
Pediatric Emergency Departments (PEDs) in low- and middle-income countries (LMICs) face significant challenges in managing infectious diseases due to limited resources, poor infrastructure, and socioeconomic barriers. This review explores the burden of infectious diseases in pediatric populations, the diagnostic tools available, treatment protocols, and preventive measures implemented in LMIC PEDs. We emphasize the need for an integrated approach to improve health outcomes, focusing on enhancing healthcare infrastructure, training healthcare workers, and promoting public health awareness. Key recommendations and future directions are discussed to address the critical gaps and challenges in managing pediatric infectious diseases in these settings.

26 January 2024 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
SESohil Elfar
Sohil Elfar
SMSomaya Abdulbaset Mahmoud
Somaya Abdulbaset Mahmoud
SHSamar Hamdi
Samar Hamdi
AEAya Ahmed Emad
Aya Ahmed Emad
MAMohamed Abd-ElGawad
Mohamed Abd-ElGawad
NTNouran A. Taha
Nouran A. Taha
Background and aim: Atrial fibrillation (AF) is the most frequently observed cardiac arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment administered, which requires a larger dose and more time to accomplish therapeutic targets due to altered pathophysiology. Our study aimed to assess the overall efficacy and safety of nonvitamin K antagonist oral anticoagulants (NOACs) versus warfarin in AF patients with morbid obesity (BMI > 40 kg/m2 and/or weight > 120 kg) to prevent complications. Methods: We conducted a literature search on PubMed, Web of Science, the Cochrane Library, and Scopus till October 2022 for articles addressing the efficacy and safety of NOACs versus warfarin for the treatment of AF in morbidly obese patients. We performed the meta-analysis with RevMan software version 5.4 and Open Meta Analyst. The main outcomes assessed were stroke, major bleeding, and minor bleeding after anticoagulation, as did the history of comorbidities and risk factors in morbidly obese patients. Quality assessment was performed using Cochrane’s ROB-2 tool and the Newcastle–Ottawa scale. Results: Regarding major bleeding events, pooled data showed that patients taking NOACs had a significantly lower risk than patients taking warfarin (OR = 0.54, 95% CI: [0.41–0.70]; p < 0.00001). However, for minor bleeding, there was a nonsignificant effect of NOACs on reducing the risk of bleeding (OR = 0.72, 95% CI = 0.47–1.09; p = 0.12), which became highly significant in favor of NOACs after sensitivity analysis (OR = 0.55, 95% CI = 0.49–0.61]; p < 0.00001). There was a significant difference in the incidence of stroke between the NOAC group and the warfarin group (OR = 0.69, 95% CI = 0.60–0.80]; p < 0.00001). According to the results of the single-arm study analysis, the overall effect of all the outcomes was associated with a high risk of disease development in patients receiving NOACs. Conclusion: Our meta-analysis showed a favorable effect of NOACs vs warfarin in morbidly obese patients. Some outcomes were not significantly different, which calls for future research to better assess their safety and efficacy in this particular weight group. Trial registration: The study was registered with PROSPERO under registration number CRD42022362493 on October 2022.

13 August 2024
Verified
Book Chapter
Closed access
PDF file
KKKhaled M. Kotb
Khaled M. Kotb
MSMohamed N. Sharafeldin
Mohamed N. Sharafeldin
HHHamsa Hassan
Hamsa Hassan
ABAchouak Boutalbi
Achouak Boutalbi
AYAhmed Yahya
Ahmed Yahya
ASAmgad E. Salem
Amgad E. Salem
Neurodegenerative diseases include diverse conditions (e.g., Parkinson’s disease and Alzheimer’s disease) in which ongoing loss of neurons and glial cells is implicated. They lead to impaired motor and cognitive functions. Although there is an advancement in therapeutic options impacting the pathogenetic mechanisms of the disease, the BBB exerts a physiological barrier that hinders their access to the brain. Thereby, novel drug delivery approaches have been considered to enhance CNS targeting and bioavailability. There is increasing evidence that lipid-based nanocarriers (e.g., liposomes) may improve brain targeting and ease BBB transportation. Nevertheless, no authorized nanoformula targets the CNS till now. We aim to summarize the relevant literature about the different types of lipid-based nanocarriers and the findings of the preclinical and clinical trials conducted so far through systematic and manual searches in PubMed. Hence, it may be inspiring to translate this approach into clinical practice and benefit from their pharmacokinetic characteristics. Moreover, we attempt to highlight the challenges and future outlooks for their implementation in clinical practice. Overall, it is still early for these applications to be translated into clinical practice due to several reasons, including safety concerns; the lack of simple formulas that can be eligible and allow affordable, large-scale production; and the absence of reliable, high-quality, and strong evidence. We suggest that there is a necessity for appropriately designed controlled trials and standardized analytical methods. <!----> <!----> <!----> <!---->

3 July 2025 in Health Policy and Technology
Verified
Journal Article
Closed access
NHNouran Hamza
Nouran Hamza
WHWael Hafez
Wael Hafez
SSSara Adel Abdelkader Saed
Sara Adel Abdelkader Saed
MSMarina Raouf Abdelmessih Saleeb
Marina Raouf Abdelmessih Saleeb
NMNesma Magdi
Nesma Magdi
NTNouran A. Taha
Nouran A. Taha

4 November 2026 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
COChibuike Daniel Onyejesi
Chibuike Daniel Onyejesi
ENElochukwu Perpetua Nwankwo
Elochukwu Perpetua Nwankwo
VOVictor N. Oboli
Victor N. Oboli
NBNwamaka Chidera Bob-Ume
Nwamaka Chidera Bob-Ume
NTNouran Ahmed Taha
Nouran Ahmed Taha
MAMohamed Alsabri
Mohamed Alsabri
Pediatric acute heart failure (AHF) is associated with substantial morbidity and mortality, but its clinical presentation, management, and outcomes in low-